Skip to main content
Clinical Trials/IRCT20151122025191N3
IRCT20151122025191N3
Recruiting
Phase 3

Evaluation of Efficacy of multidomain interventions of diet, exercise, managing of vascular risk factors and cognitive training to prevent cognitive decline in Iranian older adults

Department of health and ageing - Department of population, family and school health0 sites196 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Major neurocognitive disorder.
Sponsor
Department of health and ageing - Department of population, family and school health
Enrollment
196
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Department of health and ageing - Department of population, family and school health

Eligibility Criteria

Inclusion Criteria

  • Aged 55 to 74 years.
  • Having at least one modifiable dementia risk factor from among hypertension, diabetes mellitus, dyslipidemia, obesity, abdominal obesity, abdominal obesity, metabolic syndrome, smoking, educational level less than 9 years, physical inactivity, and social inactivity.
  • No neurocognitive disorder detected by the psychiatrist with the use of DSM5 criteria at the base time.
  • The score 85 or more in the Addenbrooke cognitive test at the base time.
  • Able to independently perform the activities of daily living.
  • Can read and write in Farsi.
  • Able to participate in the exercise program safely.
  • Having a reliable informant who can provide investigators with requested information.
  • Providing written informed consent.

Exclusion Criteria

  • Existence of major psychiatric illness such as major depressive disorder.
  • Existence of other neurodegeneration disease such as Parkinson's disease.
  • The history of malignancy within the previous 5 years.
  • The history of cardiac stent or revascularization within the previous 1 year.
  • Existence of serious or unstable medical disease such as acute or sever asthma, active gastric ulcer, sever liver disease, or sever renal disease.
  • Existence of sever loss of vision or hearing, or communication disability.
  • Existence of any conditions preventing cooperation as judged by the study physician.
  • Existence of significant laboratory abnormality that may result in cognitive impairment.
  • The simultaneous participation in any other intervention trial.

Outcomes

Primary Outcomes

Not specified

Similar Trials